PolyPid to Report Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights on February 8, 2023

Rhea-AI Summary

PolyPid Ltd. (Nasdaq: PYPD) announced it will report its fourth quarter and full year 2022 financial results on February 8, 2023, before U.S. market open. The company will conduct a conference call at 8:30 AM ET to discuss these results and business updates. PolyPid is focused on enhancing surgical outcomes through its proprietary PLEX technology, which enables sustained drug delivery. Its lead candidate, D-PLEX100, is currently in Phase 3 trials for preventing surgical site infections, while OncoPLEX is under preclinical evaluation for solid tumors.

Positive

• PolyPid's lead product candidate D-PLEX100 is in Phase 3 clinical trials.
• The company aims to improve surgical outcomes which may lead to market growth.

Negative

• None.

PETACH TIKVA, Israel, Jan. 31, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter and full year 2022 financial results and operational highlights before the open of the U.S. stock markets on Wednesday, February 8, 2023. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question of management, the Company recommends listening via the webcast.

Conference Call Dial-In & Webcast Information:

Date:	Wednesday, February 8, 2023
Time:	8:30 AM Eastern Time
Conference Call:	https://register.vevent.com/register/BIdad8bd318dec4d3cb9437ab9c40bd263
Webcast:	https://edge.media-server.com/mmc/p/rak4fxxm

About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX₁₀₀ is in Phase 3 clinical trials for the prevention of soft tissue abdominal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for treatment of solid tumors, beginning with glioblastoma.

For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.

References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.

Contacts: 

PolyPid Ltd.
Ori Warshavsky
COO – US
908-858-5995
IR@Polypid.com

Investors:
Brian Ritchie
LifeSci Advisors
212-915-2578
Britchie@lifesciadvisors.com

FAQ

When will PolyPid report its fourth quarter 2022 financial results?

PolyPid will report its fourth quarter 2022 financial results on February 8, 2023.

What time is the PolyPid conference call scheduled for?

The PolyPid conference call is scheduled for 8:30 AM Eastern Time on February 8, 2023.

What is the purpose of the upcoming PolyPid conference call?

The conference call will discuss fourth quarter financial results and provide updates on business operations.

What is PolyPid's lead product candidate?

PolyPid's lead product candidate is D-PLEX100, which is in Phase 3 clinical trials.

What technology does PolyPid use for drug delivery?

PolyPid uses its proprietary PLEX technology for locally administered, controlled, prolonged-release therapeutics.